Navigation Links
Promise for Soya Allergy Sufferers

Two Chinese soybean lines that grow without the primary protein linked to soy allergies in children and adults have been isolated by scientists//.

The two lines already are adapted to Illinois-like conditions and will be given away to breeders seeking to produce new varieties of allergy-free soybeans without genetic engineering.

Crop scientists at the University of Illinois at Urbana-Champaign and the USDA-Agricultural Research Service's Donald Danforth Plant Science Center in St. Louis screened more than 16,000 soybean lines kept in the USDA's National Soybean Germplasm Collection. The findings will appear later this year in the journal Crop Science.

The two soybean lines (PI 567476 and PI 603570A) contain virtually identical genetic mutations that do not contain the leading allergy-causing P34 protein, which consists of 379 amino acids, said Theodore Hymowitz, emeritus professor of plant genetics in the crop sciences department at the U. of I.

‘We are releasing this information with no patents so that companies and breeders involved with soybeans can incorporate these two lines as quickly as possible,’ Hymowitz said. Companies in Japan, Canada and across the United States have been following the research effort, he added.

The research, which was funded primarily by the Illinois-Missouri Biotechnology Alliance, went through two stages.

First, using a specially developed immunochemistry approach, Hymowitz's post-doctoral assistant Leina M. Joseph examined 100 lines of soybeans per day for nine months from the UI-based collection. Seeds were crushed, treated and placed on a membrane for screening. A second screening using stronger antibodies and protein gels was done to confirm the absence of P34 in the two domestic lines, Joseph said.

After the two lines were isolated, seeds were sent to the Danforth Center for additional molecular analysis to determine why P34 was absent. Six ident ical genetic mutations were found in each, indicating the two lines may be related, Hymowitz said.

‘The lack of the protein was confirmed by more-detailed two-dimensional protein assays,’ said Eliot M. Herman, a lead scientist at Danforth who probed the seeds with post-doctoral researcher Monica A. Schmidt. ‘We then isolated the gene responsible for the lesion, and we found there was a single significant change in the gene's sequence that likely produced a protein which could not be made as a stable product.’

Herman discovered P34 in the early 1990s and in 2003 had successfully used a gene-silencing technique to create a soybean line in which P34 was ‘knocked out.’ However, because of public resistance to genetically modified products researchers have been seeking a more traditional approach. Because the newly identified lines occur naturally, they can be successfully crossed into other soybean lines ‘without any biotechnology-derived component,’ the researchers noted.

‘Soybeans are slowly but surely increasingly being used in the foods we eat, and with that we are noticing an increase in the number of children and adults that have allergies to soybeans,’ Hymowitz said.

Currently, 6 percent to 8 percent of children are allergic to soy-based products, including infant formulas, while 2 percent of adults have had allergic reactions, which range from harmless skin reactions and gastrointestinal irritation to more serious facial swelling, shortness of breath, difficulty swallowing and fainting.

Avoiding soy products is becoming more difficult because of soy's use as fillers and components of many menu items. While people can read labels before preparing meals at home, avoiding soy at restaurants isn't as easy, Hymowitz said.

'"/>




Related medicine news :

1. New Prostate Cancer Vaccine Shows Promise
2. Ebola Treatment Shows Promise
3. Stem Cells Found To Offer Promise For Hair Growth
4. Promised Drug Doesnt Help Acute Heart Failure
5. Marijuana-Derived Drug Promises Hope In Treating Bladder Infection
6. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
7. New Pancreatic Cancer Vaccine Holds Promise
8. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
9. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
10. Maternal Vitamin D Supplementation Promises Healthy Bones In Child
11. Cervical Cancer Vaccine Show Promise In Prevention
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: